Literature DB >> 26823198

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).

Elena Buzzetti1, Massimo Pinzani1, Emmanuel A Tsochatzis2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and represents a growing challenge in terms of prevention and treatment. Despite its high prevalence, only a small minority of affected patients develops inflammation and subsequently fibrosis and chronic liver disease, while most of them only exhibit simple steatosis. In this context, the full understanding of the mechanisms underlying the development of NAFLD and non-alcoholic steatohepatitis (NASH) is of extreme importance; despite advances in this field, knowledge on the pathogenesis of NAFLD is still incomplete. The 'two-hit' hypothesis is now obsolete, as it is inadequate to explain the several molecular and metabolic changes that take place in NAFLD. The "multiple hit" hypothesis considers multiple insults acting together on genetically predisposed subjects to induce NAFLD and provides a more accurate explanation of NAFLD pathogenesis. Such hits include insulin resistance, hormones secreted from the adipose tissue, nutritional factors, gut microbiota and genetic and epigenetic factors. In this article, we review the factors that form this hypothesis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gut microbiome; Insulin resistance; Lipotoxicity; Metabolic syndrome; PNPLA3

Mesh:

Year:  2016        PMID: 26823198     DOI: 10.1016/j.metabol.2015.12.012

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  612 in total

1.  S-allylmercaptocysteine improves nonalcoholic steatohepatitis by enhancing AHR/NRF2-mediated drug metabolising enzymes and reducing NF-κB/IκBα and NLRP3/6-mediated inflammation.

Authors:  Qian Yu; Yann-Yin Lee; Zheng-Yun Xia; Emily C Liong; Jia Xiao; George L Tipoe
Journal:  Eur J Nutr       Date:  2020-06-17       Impact factor: 5.614

2.  Impact of miR-140 Deficiency on Non-Alcoholic Fatty Liver Disease.

Authors:  Benjamin Wolfson; Pang-Kuo Lo; Yuan Yao; Linhao Li; Hongbing Wang; Qun Zhou
Journal:  Mol Nutr Food Res       Date:  2018-06-12       Impact factor: 5.914

3.  Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway.

Authors:  Tian Shen; Bilin Xu; Tao Lei; Lin Chen; Cuiping Zhang; Zhenhua Ni
Journal:  Exp Ther Med       Date:  2018-08-01       Impact factor: 2.447

4.  Traffic-related air pollution associations with cytokeratin-18, a marker of hepatocellular apoptosis, in an overweight and obese paediatric population.

Authors:  S Hsieh; B P Leaderer; A E Feldstein; N Santoro; L A McKay; S Caprio; R McConnell
Journal:  Pediatr Obes       Date:  2017-07-20       Impact factor: 4.000

Review 5.  Roles of mitochondria in liver cancer stem cells.

Authors:  Ching-Wen Chang; Jeng-Fan Lo; Xin Wei Wang
Journal:  Differentiation       Date:  2019-05-30       Impact factor: 3.880

6.  Chemokine ligand 20 (CCL20) expression increases with NAFLD stage and hepatic stellate cell activation and is regulated by miR-590-5p.

Authors:  Amanda Hanson; Ignazio S Piras; Danielle Wilhelmsen; Christopher D Still; Xin Chu; Anthony Petrick; Glenn S Gerhard; Johanna K DiStefano
Journal:  Cytokine       Date:  2019-07-25       Impact factor: 3.861

Review 7.  Undiagnosed liver diseases.

Authors:  Emily Gao; Julian Hercun; Theo Heller; Sílvia Vilarinho
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

8.  Red Blood Cell Dysfunction in Non-Alcoholic Fatty Liver Disease: Marker and Mediator of Molecular Mechanisms.

Authors:  Charalampos Papadopoulos; Ioannis Tentes; Konstantinos Anagnostopoulos
Journal:  Maedica (Bucur)       Date:  2020-12

9.  Chrysin ameliorates nonalcoholic fatty liver disease in rats.

Authors:  Sarayu A Pai; Renuka P Munshi; Falguni H Panchal; Ila-Shruti Gaur; Archana R Juvekar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-01       Impact factor: 3.000

10.  Activin A and follistatin in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Jannis Kountouras; Athanasios D Anastasilakis; Georgios Α Triantafyllou; Christos S Mantzoros
Journal:  Metabolism       Date:  2016-07-25       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.